MML Investors Services LLC Boosts Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

MML Investors Services LLC grew its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.4% in the 4th quarter, HoldingsChannel reports. The fund owned 4,918 shares of the biopharmaceutical company’s stock after buying an additional 1,230 shares during the quarter. MML Investors Services LLC’s holdings in Alexion Pharmaceuticals were worth $588,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Ameriprise Financial Inc. grew its stake in shares of Alexion Pharmaceuticals by 3.5% in the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock worth $896,491,000 after acquiring an additional 215,005 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Alexion Pharmaceuticals by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock worth $269,251,000 after acquiring an additional 62,266 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of Alexion Pharmaceuticals by 10.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock worth $223,818,000 after acquiring an additional 174,606 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Alexion Pharmaceuticals by 32.7% in the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after acquiring an additional 383,713 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in shares of Alexion Pharmaceuticals by 21.4% in the fourth quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock worth $181,998,000 after acquiring an additional 268,053 shares in the last quarter. Institutional investors and hedge funds own 95.38% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $126.75 on Friday. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The firm has a market cap of $28,115.85, a price-to-earnings ratio of 64.67, a P/E/G ratio of 1.18 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the previous year, the company earned $1.26 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

ALXN has been the subject of several research reports. Stifel Nicolaus restated a “buy” rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Deutsche Bank set a $161.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Citigroup decreased their price objective on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research report on Friday, February 9th. Credit Suisse Group reaffirmed a “buy” rating and set a $166.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $169.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $155.22.

In related news, SVP Heidi L. Wagner sold 1,774 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the completion of the sale, the senior vice president now directly owns 47,212 shares of the company’s stock, valued at $5,491,227.72. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,253 shares of company stock valued at $3,656,229. 4.35% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/03/17/mml-investors-services-llc-boosts-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply